Related Experiment Video
Updated: Jan 6, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions
Deepanshi Sood1, Charanjit Kaur1, Naresh Kumar2
1School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Abstract:
Triple-Negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). Approximately, 10-15% of BC patients are diagnosed with triple-negative breast cancer. In this review, we have summarized the approaches used for the treatment of triple-negative breast cancer. Due to the complex genetic makeup, Triple-Negative breast cancer has high potential for metastasis and is inherently difficult to treat and poses a grave threat. This review analyzes and provides insight into advancements in treatment methods and diagnostic techniques for TNBC. Schiff base compounds, capable of inducing apoptosis in malignant cells, are effective dual inhibitors of histone deacetylase type II and topoisomerase I. Detection strategies like advanced imaging techniques like core biopsy and automated breast ultrasound are important for enhancing TNBC diagnosis and treatment. The progress in developing combination therapies and improving drug delivery mechanisms has to be maintained in order to tackle the challenges in treatment. This work emphasizes the need for teamwork in the development of therapeutic approaches, which may offer new possibilities in the treatment of TNBC.
Insights
Triple-Negative breast cancer (TNBC) is an aggressive cancer subtype. This review highlights advancements in TNBC treatment and diagnosis, including novel therapies and imaging techniques, to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Medical Imaging
Background:
- Triple-Negative breast cancer (TNBC) is the most aggressive breast cancer (BC) subtype, lacking estrogen, progesterone, and HER2 receptors.
- TNBC accounts for 10-15% of all BC cases and is characterized by high metastatic potential and treatment resistance.
- The complex genetic profile of TNBC presents significant challenges in effective management.
Purpose of the Study:
- To review current and emerging treatment modalities for Triple-Negative breast cancer.
- To analyze advancements in diagnostic techniques for enhancing TNBC detection and management.
- To provide insights into novel therapeutic strategies and combination therapies for TNBC.
Main Methods:
- Literature review summarizing research on TNBC treatment approaches.
- Analysis of diagnostic advancements, including core biopsy and automated breast ultrasound.
- Evaluation of novel therapeutic agents, such as Schiff base compounds, and drug delivery systems.
Main Results:
- Schiff base compounds show potential as dual inhibitors of histone deacetylase type II and topoisomerase I, inducing apoptosis in cancer cells.
- Advanced imaging techniques improve the accuracy and timeliness of TNBC diagnosis.
- Combination therapies and improved drug delivery mechanisms are crucial for overcoming treatment challenges.
Conclusions:
- Continued progress in combination therapies and drug delivery is essential for tackling TNBC.
- Multidisciplinary teamwork is vital for developing innovative therapeutic approaches for TNBC.
- Enhanced diagnostic strategies and novel agents like Schiff bases offer new possibilities for TNBC treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy